Several clinical trials have evaluated the efficacy and safety of Pexidartinib and PLX3397 (targeting the CSF1/CSF-1R axis) in combination with Eribulin (NCT01596751) and Paclitaxel (NCT01525602) in patients with metastatic BC, but the results are difficult to assess due to the small patient sample. Here, CSF1 is linked to breast cancer.